Andere Sprachen Sonnet BioTherapeutics Holdings, Inc.

Aktien

A3EUBF

US83548R3030

SONN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 26.06.2024			% 5 Tage	% 1. Jan.
0.9319 ^USD	+1.29%		-39.09%	-46.44%

20.06.	Top-Mittagskursrückgänge	MT
13.06.	Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics Holdings, Inc. gibt die Entwicklung und Charakterisierung von zwei neuen immuntherapeutischen Pipeline-Wirkstoffkandidaten, SON-1411 und SON-1400, bekannt, die jeweils eine Variante der IL-18 Domäne enthalten	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Top Midday Decliners	20.06.
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds	20.06.
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain	13.06.
Sonnet BioTherapeutics Holdings, Inc. Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain	13.06.
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting	28.05.
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting	28.05.
Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting	28.05.
Sonnet BioTherapeutics Announces Review of Strategic Alternatives	23.05.
Sonnet BioTherapeutics Holdings, Inc. Announces Review of Strategic Alternatives	22.05.
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target	21.05.
Sonnet BioTherapeutics : Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Form 8-K	20.05.
Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target	20.05.
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	14.05.
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference	03.05.
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy at the AACR 2024 Annual Meeting	20.03.
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	11.03.
Top Premarket Gainers	11.03.
Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080	11.03.
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers	01.03.
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update	15.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Sonnet BioTherapeutics Holdings, Inc.

Aktien

A3EUBF

US83548R3030

SONN

Andere Sprachen

Filter